

SSTR2 in glioma

Table S1. SSTR2 expression in glioma subtypes in CGGA and TCGA dataset

Diagnosis	CGGA dataset			TCGA dataset		
	Low SSTR2 expression	High SSTR2 expression	Total	Low SSTR2 expression	High SSTR2 expression	Total
glioblastoma	35 (25.18%)	104 (74.82%)	139	125 (82.24%)	27 (17.76%)	152
anaplastic oligodendroglioma	0 (0%)	12 (100%)	12	21 (24.14%)	66 (75.86%)	87
oligodendroglioma	0 (0%)	52 (100%)	52	9 (7.69%)	108 (92.31%)	117
astrocytoma	3 (5.36%)	53 (94.64%)	56	19 (34.55%)	36 (65.45%)	55
anaplastic astrocytoma	5 (13.16%)	33 (86.84%)	38	61 (53.51%)	53 (46.49%)	114




Figure S1. Kaplan-Meier curves with univariate analysis (log-rank). Patients with high SSTR2 expression were more frequently associated with better outcome than those with low SSTR2 expression in grade II glioma, grade II to III glioma and IDH wildtype glioma.

SSTR2 in glioma




Figure S2. Kaplan-Meier curves with univariate analysis (log-rank) in different glioma histological subtypes. Better prognostic trends were noted for oligodendroglioma, astrocytoma and anaplastic oligodendroglioma patients, while statistical significance was only observed in astrocytoma patients.